George V. Migausky

CIK: 0001134365

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RGNX

REGENXBIO Inc.

Director

IMVT

Immunovant, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

RGNX
REGENXBIO Inc.
May 29, 2026
Award(A)
Direct
9.8K shares-
RGNX
REGENXBIO Inc.
May 30, 2025
Award(A)
Direct
7.8K shares-
IMVT
Immunovant, Inc.
Apr 1, 2025
Award(A)
Direct
16.2K shares-

		Type	Shares	Price		Ownership
May 29, 2026	RGNX REGENXBIO Inc.	Award(A)	9,807	-	$0	Direct
May 30, 2025	RGNX REGENXBIO Inc.	Award(A)	7,768	-	-	Direct
Apr 1, 2025	IMVT Immunovant, Inc.	Award(A)	16,188	-	-	Direct

1-3 of 3 transactions

About MIGAUSKY GEORGE V

MIGAUSKY GEORGE V (SEC CIK 0001134365) files insider reports with the SEC as Director of REGENXBIO Inc. (RGNX) and Director of Immunovant, Inc. (IMVT).

Signal8 holds 3 ownership filings by MIGAUSKY GEORGE V, all Form 4s, filed between Apr 3, 2025 and Jun 2, 2026. Those filings report 3 transactions, from Apr 1, 2025 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MIGAUSKY GEORGE V's filings is in ROCKVILLE, MD.

Recent filings by MIGAUSKY GEORGE V

May 29, 2026: Grant or award of RGNX shares (Form 4, code A).
May 30, 2025: Grant or award of RGNX shares (Form 4, code A).
Apr 1, 2025: Grant or award of IMVT shares (Form 4, code A).

Other insiders filing for REGENXBIO Inc. (RGNX)

Malzahn Craig, Chief Technology Officer
Christmas Patrick J., Chief Strategy & Legal Officer
PAKOLA STEVE, Chief Medical Officer
Chan Mitchell, Chief Financial Officer
Ciongoli Gregory Austin, Director
Simpson Curran, Chief Executive Officer

How to read Form 4 transaction codes